Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Non-hematologic Malignancies Clinical Trial

Official title:

A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00948467
• Other study ID #: C20001
• Status: Completed
• Phase: Phase 1
• First received: July 27, 2009
• Last updated: July 1, 2013
• Start date: December 2009
• Est. completion date: June 2013

Study information

• Verified date: June 2013
• Source: Millennium Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and maximum tolerated dose of TAK-733 in patients with advanced, nonhematologic tumors. The expansion stage of the study will evaluate evidence of antitumor activity of TAK-733 in patients with advanced metastatic melanoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: June 2013
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Each patient must meet all of the following inclusion criteria to be enrolled in the study:

• 18 years or older.

• Have one of the following diagnoses: a nonhematologic malignancy for which standard, curative, or life-prolonging treatment does not exist or is no longer effective; OR have stage 3 or stage 4 unresectable melanoma not priorly treated with either MEK or BRAF inhibitor therapy.

• Melanoma patients should have the V600E BRAF mutation status of their tumor documented, if available, and tumor tissue must be provided for confirmatory genotyping by a central laboratory.

• Have a radiographically or clinically evaluable tumor.

• Have suitable venous access for the conduct of blood sampling.

• Provide voluntary written consent, which can be withdrawn by the patient at any time.

• Female patients who: are post-menopausal for at least 1 year before screening; OR are surgically sterile; OR if they are of childbearing potential agree to practice two effective methods of birth control from the time of signing the informed consent form through 30 days after the last dose of the study drug, or agree to completely abstain from heterosexual intercourse.

• Male patients, even if surgically sterilized, must agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of the study drug; OR agree to completely abstain from heterosexual intercourse.

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

• Female patients who are lactating or have a positive serum pregnancy test during the Screening period.

• Antineoplastic therapy or radiotherapy within 21 days; or nitrosoureas of mitomycin C within 42 days

• Prior biologic or immunotherapy = 4 weeks prior to enrollment.

• Grade 2 or greater unresolved toxicity (except alopecia) from previous anticancer therapy.

• Major surgery within 14 days of the first dose of the study drug.

• An active infection requiring systemic therapy; or other severe infection.

• Symptomatic brain metastases.

• Inability to meet specific laboratory test standards during the Screening period as specified in the study protocol.

• Human Immunodeficiency (HIV) positive.

• Hepatitis B surface antigen positive or active hepatitis C infection.

• Serious medical or psychiatric illness likely to interfere with the study.

• Uncontrolled cardiovascular condition.

• Abnormalities on 12-lead ECG performed within 28 days before the start of the study drug that are considered to be clinically significant or rate corrected QT interval > 470 milliseconds.

• Melanoma patients will be excluded if they have had a diagnosis with or treatment for another malignancy within 2 years of the first dose of the study drug, or have been previously diagnosed with another malignancy with any evidence of residual disease.

• Treatment with any investigational product within 28 days before the first dose of the study drug.

• A history of an ongoing or newly diagnosed eye abnormality, such as retinal or corneal pathologies.

• Abnormal left ventricular ejection fraction (LVEF).

• Receiving therapeutic anticoagulation

• Treatment with any of the following strong CYP3A inhibitors or inducers within 14 days before the first dose of study drug: ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, rifampin, rifapentine, or rifabutin.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Advanced Metastatic Melanoma
• Advanced Non-hematologic Malignancies
• Neoplasms

Intervention

Drug:
• TAK-733
The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days. The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.

Locations

Country	Name	City	State
United States	Roswell Park Cancer Institute	Buffalo	New York
United States	Wayne State University Karmanos Cancer Institute	Detriot	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety profile, dose-limiting toxicities, maximum tolerated dose and recommended phase 2 dose of TAK-733		12 months	Yes
Primary	Pharmacokinetic characterization of TAK-733		12 months	No
Secondary	Effect of food on the pharmacokinetics of TAK-733		12 months	No
Secondary	Antitumor activity of TAK-733 in patients with advanced nonhematologic malignancies		12 months	No
Secondary	Antitumor activity of TAK-733 in melanoma patients		12 months	No